Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Journal of Asthma and Allergy|January 30, 2023
Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with AsthmaRichard N van Zyl-Smit, Kenneth R Chapman, Huib A M Kerstjens, et al.
Clinical Pharmacology in Drug Development|February 23, 2024
Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy VolunteersRamachandra Sangana, Yan Xu, Bharti Shah, et al.
Asian Pacific Journal of Allergy and Immunology|April 6, 2020
Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and CaucasiansJing Li, Jing Yang, Lingfei Kong, et al.
BJU International|November 26, 2010
Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710)Emil Scosyrev, Benjamin W Ely, Edward M Messing, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 4, 2026
Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trialsAna Maria Giménez-Arnau, Artem Zharkov, Bin Yang, et al.
The New England Journal of Medicine|March 30, 2026
Iptacopan in IgA Nephropathy - Final 24-Month DataJonathan Barratt, Necmi Eren, Naoki Kashihara, et al.
Lancet (London, England)|November 26, 2023
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trialsMarcus Maurer, Luis Felipe Ensina, Ana Maria Gimenez-Arnau, et al.
Pageof 5